Navigation Links
Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
Date:8/20/2007

ystemic formulation of humanized form of Sphingomab(TM)) is an antibody against S1P that holds promise for the treatment of cancer and other diseases. A second product candidate, iSONEP(TM) (the ocular formulation of humanized Sphingomab), has demonstrated superior results in various preclinical AMD models. Lpath's third product candidate, Lpathomab(TM), is an antibody against LPA, a key bioactive lipid that has been long recognized as a valid disease target. The company's unique ability to generate novel antibodies against bioactive lipids is based on its ImmuneY2(TM) drug-discovery engine, which the company is using to add to its pipeline. For more information, visit http://www.Lpath.com

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that required clinical trials will be successful, necessary regulatory approvals will be obtained, or the proposed treatments will prove to be safe or effective. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, our limited experience in the development of therapeutic drugs, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on research grants, current and future competition, and other risks described from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances aris
'/>"/>

SOURCE Lpath, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Lpath Demonstrates First-in-Class AMD Results With Its Lead Drug Candidate, Sphingomab
2. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
7. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
8. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
9. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
10. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
11. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... OAKS, Calif., July 29, 2014 Amgen (NASDAQ: ... the second quarter of 2014. Key results include: ... with 8 percent product sales growth driven by strong ... Kyprolis ® (carfilzomib), Prolia ® (denosumab) and ... 25 percent to $2.37, driven by higher revenues and ...
(Date:7/29/2014)... RIDGE, N.J. , July 29, 2014 ... biopharmaceutical company focused on the Phase 3 clinical development ... actively controllable antithrombotic drug system, today announced that it ... on Tuesday, Aug. 12, 2014, at 8:30 a.m. EDT ... corporate highlights. Interested participants and investors may ...
(Date:7/29/2014)... ST. PAUL, Minn. , July 29, 2014 /PRNewswire/ ... of medical devices using neuroblocking technology to treat obesity, ... it will host a conference call on Thursday, August ... financial results for the second quarter ended June 30, ... Conference Call Details The second quarter conference ...
Breaking Medicine Technology:Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3
...   Delcath Systems, Inc. (NASDAQ: DCTH ) ... Board. "As a widely respected hepatologist ... (ILCA), Dr. Gores will contribute a wealth of clinical ... our Medical Advisory Board," said Eamonn P. Hobbs, CEO ...
... PLEASANTON, Calif., Dec. 21, 2011  TriReme Medical, Inc. ... the treatment of complex vascular disease, announced today ... U.S. Food and Drug Administration to market its ... of occluded peripheral arteries. Chocolate was developed in ...
Cached Medicine Technology:Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 2Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 3Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 4TriReme Medical, Inc. Receives FDA 510(K) Clearance for Chocolate PTA Balloon Catheter 2
(Date:7/30/2014)... Frozen shoulder (Adhesive capsulitis) affects 10-20 percent of people ... condition which occurs most frequently in people between the ages ... and half years if not treated. , Adhesive capsulitis is ... it can render your shoulder so stiff, it's almost impossible ... in too much pain to get dressed in the first ...
(Date:7/30/2014)... Amy Norton HealthDay Reporter ... time in a garden might help soothe the agitation that ... Looking at 17 past studies, British researchers found evidence that ... help soothe some dementia patients, anxiety. The study authors ... a tough subject to study -- and the evidence of ...
(Date:7/30/2014)... Young adults who were breastfed for three months ... risk of chronic inflammation associated with cardiovascular and ... School at Washington University in St. Louis. , ... have implications for children,s health decades later," said ... Brown School and a co-author of the study ...
(Date:7/30/2014)... 30, 2014 Everyone knows that the internet ... everyone. Whether people are looking for something to buy, trying ... dentist, the internet is pretty much always going to be ... in Lauderdale Florida is so happy to announce the launch ... presence into the modern age. Whether a person wants to ...
(Date:7/30/2014)... The North America aviation actuator market is ... America is expected to be the fastest growing region ... of 5.60%. , The commercial aircraft market offers ... assume prominence in the years to come. Commercial aviation ... has regained quickly, and the industry has been reliably ...
Breaking Medicine News(10 mins):Health News:Good News for Diabetics Suffering from Frozen Shoulder 2Health News:Good News for Diabetics Suffering from Frozen Shoulder 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 4Health News:Gardens a Center of Calm for People With Dementia 2Health News:Gardens a Center of Calm for People With Dementia 3Health News:Birthweight and breastfeeding have implications for children's health decades later 2Health News:Sierra Dental Releases New Website For Fort Lauderdale Residents 2Health News:North America Aviation Actuation System Market is Expected to Reach $1781.02 million in 2019 - New Report by MicroMarket Monitor 2Health News:North America Aviation Actuation System Market is Expected to Reach $1781.02 million in 2019 - New Report by MicroMarket Monitor 3Health News:North America Aviation Actuation System Market is Expected to Reach $1781.02 million in 2019 - New Report by MicroMarket Monitor 4
... , FRIDAY, Aug. 5 (HealthDay News) -- Believing in a ... ability to cope with uncertainty, researchers report. The paper, ... includes the results of two studies conducted by researchers at ... study of 332 Christians and Jews found that those who ...
... -- Smoking increases the risk of developing a heart rhythm ... researchers reviewed data from more than 15,000 people, aged 45 ... years, and found that there were 876 atrial fibrillation events ... rhythm was 1.32 times higher in former smokers and two ...
... FRIDAY, Aug. 5 (HealthDay News) -- For older Americans who ... that performance often trumps appearance. The boost in body ... exercise proved more satisfying than any change in appearance, especially ... advancing years, a shift in emphasis may occur, one that ...
... News) -- Children with HIV who receive antiretroviral treatments ... levels, and would benefit from guidelines aimed at reducing ... are published in JAIDS: Journal of Acquired Immune ... crucial step in minimizing cardiovascular disease complications and maximizing ...
... of Sexual Medicine reveals that in obese men ... sexual desire and lowers urinary tract symptoms. Researchers ... of the University of Adelaide studied 31 obese men ... received either a meal replacement-based low-calorie diet or a ...
... available in Spanish . , ANN ARBOR, Mich. ... can be used safely and effectively even in tumors from ... from the University of Michigan Comprehensive Cancer Center. Sentinel ... the first node where cancer would likely spread. If that ...
Cached Medicine News:Health News:Less Worry, Better Coping Seen Among Religious Folks 2Health News:With Age, Focus on Body Shifts From Appearance to Function 2Health News:With Age, Focus on Body Shifts From Appearance to Function 3Health News:Children's HIV Drugs May Cause High Cholesterol 2Health News:Sentinel node biopsy safe, effective in head and neck melanomas, U-M study finds 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: